CL2023001565A1 - Inhibidores de enzimas - Google Patents

Inhibidores de enzimas

Info

Publication number
CL2023001565A1
CL2023001565A1 CL2023001565A CL2023001565A CL2023001565A1 CL 2023001565 A1 CL2023001565 A1 CL 2023001565A1 CL 2023001565 A CL2023001565 A CL 2023001565A CL 2023001565 A CL2023001565 A CL 2023001565A CL 2023001565 A1 CL2023001565 A1 CL 2023001565A1
Authority
CL
Chile
Prior art keywords
compounds
enzyme inhibitors
formula
present
medicine
Prior art date
Application number
CL2023001565A
Other languages
English (en)
Inventor
Lewis Childs Mitchell
Louise Davie Rebecca
Joy Edwards Hannah
Michael Evans David
Jack Greves William
Teanby Hodgson Simon
Mazzacani Alessandro
Leslie North Carl
Stela Obara Alicja
Bryan Roe Michael
Philip Rooker David
John Stocks Michael
Michelle Birch Louise
Pichowicz Mark
Pittaway Rachael
John Smith Alun
Eric THROUP Adam
William Wrigglesworth Joseph
Yang Xuezheng
Edward Clark David
Original Assignee
Kalvista Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2018970.0A external-priority patent/GB202018970D0/en
Application filed by Kalvista Pharmaceuticals Ltd filed Critical Kalvista Pharmaceuticals Ltd
Publication of CL2023001565A1 publication Critical patent/CL2023001565A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención proporciona compuestos de fórmula (I); composiciones que comprenden tales compuestos; el uso de tales compuestos en medicina; y métodos para tratar a los pacientes con tales compuestos; donde A, W, R5, n, Z, X, Y y B son como se definen en el presente documento. Además, la presente invención se refiere a compuestos útiles como intermedios sintéticos de compuestos de fórmula (I).
CL2023001565A 2020-12-01 2023-06-01 Inhibidores de enzimas CL2023001565A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063120074P 2020-12-01 2020-12-01
GBGB2018970.0A GB202018970D0 (en) 2020-12-01 2020-12-01 Enzyme inhibitors

Publications (1)

Publication Number Publication Date
CL2023001565A1 true CL2023001565A1 (es) 2023-11-17

Family

ID=78844690

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023001565A CL2023001565A1 (es) 2020-12-01 2023-06-01 Inhibidores de enzimas

Country Status (13)

Country Link
US (1) US20240059691A1 (es)
EP (1) EP4255900A2 (es)
JP (1) JP2023552747A (es)
KR (1) KR20230128413A (es)
AU (1) AU2021393080A1 (es)
BR (1) BR112023010200A2 (es)
CA (1) CA3203922A1 (es)
CL (1) CL2023001565A1 (es)
CO (1) CO2023008475A2 (es)
IL (1) IL303267A (es)
MX (1) MX2023006231A (es)
TW (1) TW202237578A (es)
WO (1) WO2022118016A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024038282A1 (en) * 2022-08-18 2024-02-22 Kalvista Pharmaceuticals Limited 2-aza- and 2-oxabicyclo[2.1.1]hexane derivatives as factor xiia enzyme inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6878714B2 (en) * 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
CN1934255B (zh) 2003-08-27 2012-07-11 奥普索特克公司 用于治疗眼新血管疾病的组合治疗
WO2008086462A2 (en) * 2007-01-11 2008-07-17 Wyeth AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF β-CANTENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS
US20130310379A1 (en) * 2010-11-19 2013-11-21 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
JP6109081B2 (ja) 2011-03-09 2017-04-05 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 人工表面との接触を含む医学的手技に伴う投与のためのｆｘｉｉ阻害剤
US9815853B2 (en) * 2015-06-12 2017-11-14 Global Blood Therapeutics, Inc. Bridged bicyclic kallikrein inhibitors
CN106854207B (zh) * 2015-12-08 2019-10-29 上海赛默罗生物科技有限公司 呔嗪类衍生物、其制备方法、药物组合物和用途
WO2017123518A1 (en) 2016-01-11 2017-07-20 The Rockefeller University Aminotriazole immunomodulators for treating autoimmune diseases
CN109475530B (zh) 2016-05-23 2022-03-01 洛克菲勒大学 用于治疗自身免疫性疾病的氨酰基吲唑免疫调节剂
CN108699002B (zh) * 2016-11-11 2021-11-09 上海海雁医药科技有限公司 1,5,7-三取代的异喹啉衍生物、其制法与医药上的用途
EP3541375B1 (en) 2016-11-18 2023-08-23 Merck Sharp & Dohme LLC Factor xiia inhibitors
US11014920B2 (en) 2016-11-18 2021-05-25 Merck Sharp & Dohme Corp. Factor XIIa inhibitors
AU2018375308A1 (en) * 2017-11-29 2020-06-25 The Rockefeller University Pyranopyrazole and pyrazolopyridine immunomodulators for treatment of autoimmune diseases
GB201805174D0 (en) 2018-03-29 2018-05-16 Univ Leeds Innovations Ltd Compounds
GB201807014D0 (en) 2018-04-30 2018-06-13 Univ Leeds Innovations Ltd Factor xlla inhibitors

Also Published As

Publication number Publication date
TW202237578A (zh) 2022-10-01
IL303267A (en) 2023-07-01
KR20230128413A (ko) 2023-09-04
CA3203922A1 (en) 2022-06-09
WO2022118016A3 (en) 2022-07-07
JP2023552747A (ja) 2023-12-19
AU2021393080A9 (en) 2024-05-02
BR112023010200A2 (pt) 2024-02-06
EP4255900A2 (en) 2023-10-11
MX2023006231A (es) 2023-08-24
WO2022118016A2 (en) 2022-06-09
US20240059691A1 (en) 2024-02-22
CO2023008475A2 (es) 2023-10-30
AU2021393080A1 (en) 2023-07-20

Similar Documents

Publication Publication Date Title
CO2022010241A2 (es) Inhibidores de sos1
CL2023002090A1 (es) Inhibidores de kras tricíclicos fusionados
CO2017009891A2 (es) Inhibidores de inhibidores del factor beta de crecimiento de transformación (tgf-beta)
CL2022000603A1 (es) Inhibidores prmt5 cooperativos de mta
CO2019009373A2 (es) Compuestos heterocíclicos útiles como inhibidores duales de atx/ca.
CO2022000481A2 (es) Inhibidores de enzimas
BR112012023421A2 (pt) composição farmacêutica para tratamento de aumento de pressão intraocular
ECSP10010129A (es) Inhibidores de quinasas símil polo
CO2022002000A2 (es) Nuevos inhibidores heterocíclicos de monoacilglicerol lipasa (magl)
CO2024001285A2 (es) Compuestos tricíclicos como inhibidores de kras
CO2023004195A2 (es) Compuestos heterocíclicos
CU20200008A7 (es) Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas, métodos para preparar dichos compuestos y composiciones farmacéuticas que los contienen
CO2023008475A2 (es) Inhibidores de enzimas
CO2023014721A2 (es) Compuestos heterocíclicos
CL2020002217A1 (es) Uso de alcoxipirazoles como inhibidores de la nitrificación
CO2021013166A2 (es) Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria
CL2020002216A1 (es) Uso de compuestos de alcoxi pirazol funcionalizados con n como inhibidores de la nitrificación
CL2021001656A1 (es) Compuestos de imidazopiridina e imidazopiridina y sus usos.
CO2023013469A2 (es) Derivados de fósforo como nuevos inhibidores de sos1
ECSP22026478A (es) Inhibidor de diacilglicerol aciltransferasa 2
CO2023012342A2 (es) Inhibidores de enzimas
CL2022003206A1 (es) Compuestos derivados de quinolona y su uso para el tratamiento del cáncer (div. sol. 202102501)
UY39434A (es) Nuevos compuestos
BR112023015721A2 (pt) Derivados tricíclicos úteis como inibidores de parp7
CL2022000217A1 (es) Inhibidores de enzimas